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ABSTRACT 
Murva (Maerua oblongifolia) contains numerous bioactive compounds that may provide multiple health benefits, including anti-
microbial, anti-fungal, anti-pyretic and anti-diabetic. Most of the therapeutic effects of murva have been attributed due to the 
presence of triterpenoids and alkaloids, in their composition. Although these compounds have been shown promising therapeutic 
effects under in-vitro conditions, they met with limited efficacy in clinical settings due to various reasons such as poor oral 
absorption and bioavailability. Different techniques have been proposed to improve the stability and bioavailability of the herbal 
drugs. Among such strategies, nanoparticulate based drug delivery systems are novel and promising tools. In this study, chitosan 
nanoparticles containing Murva (CNP1-CNP3) were synthesized by ionic gelation technique, which resulting in particles size 
smaller than 650nm. The encapsulation efficiency of nanoformulations was over 41.5%. The nanoformulations exhibited slow and 
sustained in vitro release over 99% of drug from the Murva encapsulated chitosan nanoparticles after 24 hours. The synthesized 
nanoformulations were found to be a promising system for oral sustained administration of murva and also enhance its stability and 
bioavailability. 
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INTRODUCTION 
Murva is one of the potent phytomolecule, obtained from 
Maerua oblongifolia (Forssk.) A. Rich.) of family 
Capparaceae, has been traditionally used to cure various 
diseases
1
.  Ethanomedical survey reveals that Murva 
(Maerua oblongifolia) is used to cure various diseases 
such as fever, stomach ache, skin infections, urinary 
calculi, diabetes mellitus, epilepsy, pruritis, rigidity in 
lower limbs, abdominal colic and cough
2
. Most of the 
therapeutic effects of murva have been attributed due to 
the presence of triterpenoids and alkaloids, in their 
composition. Although these compounds have been 
shown promising therapeutic effects under in-vitro 
conditions, they met with limited efficacy in clinical 
settings due to various reasons such as poor oral 
absorption and bioavailability. Different techniques have 
been proposed to improve the stability and 
bioavailability of the herbal drugs. Among such 
strategies, nanoparticulate-based drug delivery systems 
are novel and promising tools. 
Nanoparticulate drug delivery systems may increase 
drug/bioactive levels by avoiding presystemic hepatic 
metabolism
3
. Nanoparticulate-based delivery systems 
may enhance oral absorption of drug/bioactive by 
increasing the gastric residence time through mucosal 
adhesion
4
 or by increasing cell or tissue entry
5,6
 (e.g., 
Peyer’s patches and M cell-mediated uptake). 
Nanoparticles formulations may reduce the drug 
exposure to the adverse conditions in the GI tract, 
thereby minimizing enzymatic and non-enzymatic 
degradations, and this can result in increased plasma 
exposure of the bioactive. The encapsulation of 
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drug/bioactive molecules in nanoparticles can 
significantly reduce their apparent clearance from 
plasma, thereby enhancing the apparent drug/bioactive 
circulation half-life and potential cumulative 
drug/bioactive delivery to the target tissues
7
. 
Most of the investigated nanoparticulate-based delivery 
system for herbal drugs was chitosan nanoparticles. 
Chitosan, a  linear polymer composed of  randomly 
distributed β-(1-4)-linked D- glucosamine and N-acetyl-
D-glucosamine, is the only alkaline natural 
polysaccharide with  degradable, biocompatible and  
film- forming properties
8
. Chitosan possess some unique 
properties such as  controlled release, in  situ  gelling, 
mucoadhesion,  hydrophilic character,  transfection  
enhancing, permeation  enhancing, and efflux  pump 
inhibitory properties, which make it  an  ideal candidate  
for   drug  delivery  applications
9-11
.  Chitosan possess 
positive charge and therefore bind strongly to negatively 
charged surfaces, and this feature is responsible for many 
of observed biological activities
12
. Chitosan nanoparticles 
have the ability to prevent oxidation/degradation of 
herbal drug encapsulated within them in GI tract
13
. 
Chitosan nanoparticle carrier has been shown to inhibit 
intestinal P-gp (ABC trans- porter) and enhance nutrient 
oral absorption
14
. This study was aimed to synthesize 
Chitosan nanoparticles loaded with Murva to improve 
the stability and bioavailability by evaluating their 
entrapment efficiency, particle size and in-vitro drug 
release. 
MATERIALS AND METHODS 
Materials:  
Chitosan, Glacial acetic acid, sodium tripolyphosphate 
were purchased from Otto Kemi, Mumbai. All other 
chemicals used were of analytical grade. 
Methods: 
Preparation of herbal nanoparticles of Murva 
Herbal nanoparticles were prepared by ionic gelation 
method as reported by Calvo. et. al.,(1997)
15
 with slight 
modification. The nanoparticles were easily prepared 
upon the addition of TPP to a chitosan solution 
containing Murva and mixing by using magnetic stirrer. 
Encapsulating polymer solution was prepared by 
dissolving chitosan in glacial acetic acid solution to 
achieve 1%, 3% and 5% (W/V) of different 
formulations. Drug solution was prepared separately by 
dissolving Murva (10 mg) in water. The chitosan and 
drug solutions were mixed together using magnetic 
stirrer (25°C, 30 min) and 0.25% (w/v) TPP was added 
drop-wise while stirring. During the ionic interaction of 
chitosan with TPP establishes an equilibrium leading to 
the reduction of the aqueous solubility of chitosan
16
. In 
this process, it traps the Murva into the core to 
encapsulate resulting in nanoformulations. The resultant 
nanoparticles suspension was centrifuged (10,000 rpm, 
30 min), the particles were washed thrice with distilled 
water and freeze dried. While preparing nanoparticles, it 
is critical to regulate the ratio between chitosan and TPP 
in order to control the uniform size of the nanoparticles 
in the reacting mixture. The procedure was repeated for 
all the three formulations CNP1, CNP2 and CNP3 
prepared
17-21
.
 
Table 1: Formula for preparation of Chitosan nanoparticles 
S.No Formulation 
Code 
Murva 
(mg) 
Chitosan (%) Curcumin : 
Chitosan ratio 
0.25%TPP 
solution (ml) 
0.1% Acetic acid 
solution (ml) 
1 CNP1 10 0.1 1:1 10 100 
2 CNP2 10 0.3 1:3 10 100 
3 CNP3 10 0.5 1:5 10 100 
 
Evaluation of Entrapment Efficiency 
The entrapment efficiency is also known as Association 
Efficiency. The drug loaded nanoparticles are 
centrifuged at a high speed of 3500-20000 rpm for 30 
min and the supernatant is assayed for non-bound drug 
concentration by UV spectrophotometer at 365nm
22
. 
The percentage Drug Entrapment Efficiency was 
calculated as follows:       
                       
                   
                                
 X 
100 
Particle Size analysis 
The particle size was analyzed by Zeta sizer Nano ZS 
(Malvern Instruments, UK). For the analysis, the 
nanoparticles sample of the desired concentration was 
flushed through a folded capillary cell (DTS1060) and 
the measurement was carried out on the second filling; a 
sufficient sample volume was used to completely cover 
the electrodes of the cell. The sample was injected 
slowly and analysis was carried out if there were no 
visible air bubble inclusions present. After inspection, 
the cell was placed into the Zetasizer and equilibrated at 
for 2 min prior to the particle size measurements. 
Scanning Electron Microscopy (SEM)  
The surface morphology of the chitosan nanoparticles 
were studied using Scanning electron microscopy (SEM 
Jeol JSM-6400, JAPAN) operating at 20kv. The 
samples are mounted on a metal stub with double 
adhesive type and coated with platinum/palladium alloy 
under vacuum.
 
The results were given in results and 
discussion section. 
In-vitro Release Studies  
Dissolution  studies  were  carried  out  by  using  USP  
dissolution  test  apparatus. Capsule filled with 
nanoparticles equivalent to 10 mg of drug was placed in 
dissolution media in dissolution apparatus. In order to 
Arulanandraj et al                                                                                           Journal of Drug Delivery & Therapeutics. 2018; 8(5):251-256           
ISSN: 2250-1177                                                                             [253]                                                                             CODEN (USA): JDDTAO 
 
 
simulate the pH changes along the GI tract, three 
dissolution media with pH 1.2, 7.4 and 6.8 were 
sequentially used referred to as sequential pH change 
method. When performing experiments, the pH 1.2 
medium was first used for 2 hours (since the average 
gastric emptying time is 2 hrs.), then removed and the 
fresh pH 7.4 phosphate buffer saline was added. After 3 
hours (average small intestinal transit time is 3 hrs.), 
then the medium was removed and colonic fluid pH 6.8 
buffer was added for subsequent hours. 900ml of the 
dissolution medium was used at each time. 
Rotation speed was 100 rpm and temperature was 
maintained at 37±0.5⁰C. 5 ml of dissolution media was 
withdrawn at predetermined time intervals and fresh 
dissolution media was replaced. The samples were 
withdrawn at specified intervals and analyzed at 365 nm 
by UV absorption spectroscopy and the cumulative 
percentage release was calculated over the sampling 
times. 
Accelerated stability study: 
The nanoparticles from the selected and optimized batch 
was studied for stability and kept under the accelerated 
conditions of temperature and moisture (humidity) for 
the period of six months. This nanoparticles stability 
was studied at three different temperature conditions, i.e 
4
o
C, Room Temperature and 45
o
C for 6 months. Every 
sample separately weighed and enclosed by aluminium 
foils and sealed. The samples were kept in specified 
conditions for a period of six months. The samples were 
collected at specific time intervals and measured for the 
amount of drug release using UV-Spectrophotometer at 
365nm.  
RESULT AND DISCUSSION 
Chitosan Nanoparticles: Formulation and Evaluation  
Chitosan Nanoparticles were successfully formulated 
and evaluated. All the formulations were white in 
colour. The particles obtained were of smooth and free 
flowing. Chitosan nanoparticles were prepared by ionic 
gelation technique based on the ionic interaction of a 
positively charged chitosan solution and negatively 
charged TPP solution. The charge density of both 
chitosan and TPP solution has a great effect on the ionic 
interaction.  No visible impurity was seen in the 
prepared chitosan nanoparticles.  
Entrapment Efficiency of Chitosan Nanoparticles 
The entrapment efficiency of chitosan nanoparticles 
increased with increase in polymer concentration. The  
entrapment  efficiencies  were  found  to  be  minimum  
and  maximum  of  41.5±2.6% and 87.3±0.8%  
respectively. From the drug content and entrapment 
efficiency results, the formulation CNP5 was considered 
as an optimum trial. The results were given in the table 
2.
 
Table 2: Drug content and Entrapment efficiency of chitosan nanoparticles 
S.No Formulation Code Curcumin : Chitosan ratio Entrapment efficiency (%) 
1 CNP1 1:1 41.5±2.6 
2 CNP2 1:3 64.7±3.7 
3 CNP3 1:5 87.3±0.8 
n=3   mean±SD 
\ 
 
Figure 1: Entrapment  ef f iciency of chitosan 
nanoparticles 
Particle Size of Chitosan Nanoparticles  
The particle size of chitosan nanoparticles varied from 
360±12nm to 622±42nm. The mean particle size of 
chitosan nanoparticles was reduced from CNP1 
(622±42nm) to CNP3 (360±12nm) with increase in 
polymer concentration. This may be due to avoidance of 
aggregation of drug particles. The particle size of the 
chitosan nanoparticles (CNP1-CNP3) were given in the 
table 3. 
  
Table 3: Particle Size of chitosan nanoparticles  
S.No Formulation Code Curcumin : Chitosan ratio Particle Size (nm) 
1 CNP1 1:1 622±42 
2 CNP2 1:3 582±42 
3 CNP3 1:5 360 ±12 
n=3  mean±SD 
 
0 
50 
100 
CNPI CNP2 CNP3 
Entrapment efficiency (%) 
Entrapment efficiency of chitosan 
nanoparticles 
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Figure 2: Particle Size of Chitosan Nanoparticles 
Scanning Electron Microscopy: 
The surface morphology of the selected optimized 
formulation (CNP3) was determined by scanning 
electron microscopy (SEM) for characterization of 
nanoparticles. The result shows that the prepared 
nanoparticles were spherical, discrete and having a 
smooth to rough surface. 
 
Figure 3: Scanning electron microscopy of CNP3 
formulation 
In-Vitro Release Studies:    
The prepared formulations (CNP1–CNP3) were 
subjected to in-vitro release studies. Absolutely, there 
was no drug release in simulated gastric fluid (acidic pH 
1.2) for initial 2 hours. The drug release was found in 
simulated intestinal fluid (pH 7.4 phosphate buffer) and 
in colonic medium (pH 6.8 phosphate buffer).   
In-vitro release profiles in intestinal/colonic medium 
were found to have very good controlled efficacy. 
During dissolution study it was found that, the drug 
release depends upon the nature of the polymer matrix 
as well as the pH of the media. In common increase in 
polymer concentration produced much more time for 
release of drug for all formulations. The drug release 
was decreased and sustained with increase in polymer 
concentration. 
Chitosan nanoparticles prepared with 0.5% chitosan 
(CNP3) showed controlled and sustained drug release 
for a period of 24 hr. The percentage cumulative drug 
release of CNP3 at the end of 24 hr was found to 
be 99.74±0.26%. The results were given in the table 4. 
Table 4: In vitro release of chitosan nanoparticles 
(CNP1 to CNP3) 
Time 
(hrs) 
% Cumulative drug release 
CNP1 CNP 2 CNP 3 
0 0 0 0 
1 0 0 0 
2 0 0 0 
4 45.83±0.85 29.13±0.28 17.17±0.22 
6 83.77±0.64 58.88±0.42 35.54±0.09 
8 97.36±0.52 85.79±0.31 70.35±0.35 
12 98.33±0.36 95.23±0.36 85.39±0.27 
16 99.14±0.25 97.65±0.18 91.47±0.46 
20 - 99.48±0.25
- 
95.81±0.38 
24 - - 99.74±0.26 
n = 3; Mean ± S.D 
 
 
Figure 4: In-vitro drug release of the chitosan 
nanoparticles (CNP1-CNP3) 
Stability studies 
The prepared nanoparticle formulations were subjected 
to stability studies as per ICH guidelines. The samples 
were kept at three different temperature conditions, i.e 
4
o
C, Room Temperature and 45
o
C for 6 months. 
Samples were withdrawn at predetermined time 
intervals of 0, 1, 2, 3 and 6 months and then evaluated 
for the drug release. The result showed a slight 
degradation at the elevated temperature (45
o
C) in 
comparison with 4
o
C and room temperature. This 
suggests that the formulations were stable under normal 
conditions. However the ideal storage of the 
nanoparticles formulation at temperatures of 25
o
C or 
less may be more suitable for stability purposes. Further, 
none of the nanoparticles formulations indicated any 
symptoms of agglomeration or colour change during the 
period of assessment. 
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Table 5: Stability study of chitosan nanoparticles (CNP1, CNP2 and CNP3) 
 
Sl. No 
 
Time in 
months 
CNP1 Formulation CNP2 Formulation CNP3 Formulation 
4
o
C Room 
Temp 
45
o
C 4
o
C Room 
Temp 
45
o
C 4
o
C Room 
Temp 
45
o
C 
1 0 100 100 100 100 100 100 100 100 100 
2 1 97.02 94.99 94.64 98.01 97.89 95.65 99.47 99.05 95.03 
3 2 97.67 96.68 92.01 96.55 97.01 94.90 98.11 98.16 95.98 
4 3 96.42 97.79 91.44 97.99 98.66 97.10 97.12 97.88 96.12 
5 6 94.78 92.04 90.42 96.04 95.67 89.11 96.68 96.21 92.33 
 
 
 
 
Figure 5: Stability study of chitosan nanoparticles (CNP1, CNP2 and CNP3). 
 
SUMMARY AND CONCLUSION 
In the present work, the study was carried out with a 
view to increase the stability and bioavailability of the 
herbal drug Murva. Chitosan nanoparticles were 
successfully prepared by ionic gelation method using 
TPP as a crosslinking agent by varying the concentration 
of Chitosan. Chitosan nanoparticles (CNP1-CNP3) 
showed entrapment efficiency from 41.5-87.3%, particle 
size ranges from 360-622 nm) and in-vitro drug releases 
were over 99%. The in-vitro drug release study showed 
that the release of the drug from the formulation CNP3 
was more sustained when compared with other 
formulations. The formulations (CNP1, CNP2) showed 
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quick release of drug. Stability studies confirmed that all 
the nanoparticles preparations were stable at room 
temperature and or less may be more suitable for 
stability purpose. Hence it can be concluded that the 
newly developed formulation- nanoparticulate drug 
delivery system of murva with Chitosan is considered to 
be potential and effective agent to enhance the 
bioavailability and stability. 
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